Fed. Circ. Wipes Out $1.1B Juno IP Win On Cancer Drug
The Federal Circuit on Thursday reversed a $1.1 billion judgment against Gilead's Kite Pharma Inc. for infringing Bristol-Myers cancer immunotherapy patent, ruling that the patent is invalid because it lacks adequate...To view the full article, register now.
Already a subscriber? Click here to view full article